\BOOKMARK [1][-]{section.1}{Introducci\363}{}% 1
\BOOKMARK [2][-]{subsection.1.1}{Hist\362ria}{section.1}% 2
\BOOKMARK [2][-]{subsection.1.2}{Mutacions}{section.1}% 3
\BOOKMARK [2][-]{subsection.1.3}{Malalties monog\350niques}{section.1}% 4
\BOOKMARK [2][-]{subsection.1.4}{Diagn\362stic}{section.1}% 5
\BOOKMARK [2][-]{subsection.1.5}{Malalties monog\350niques per p\350rdua de funci\363}{section.1}% 6
\BOOKMARK [1][-]{section.2}{Malalties autos\362miques recessives}{}% 7
\BOOKMARK [2][-]{subsection.2.1}{Intoler\340ncia a la lactosa}{section.2}% 8
\BOOKMARK [2][-]{subsection.2.2}{Intoler\340ncia heredit\340ria a la galactosa}{section.2}% 9
\BOOKMARK [2][-]{subsection.2.3}{Intoler\340ncia heredit\340ria a la fructosa}{section.2}% 10
\BOOKMARK [2][-]{subsection.2.4}{Defici\350ncia en 21-hidroxilasa}{section.2}% 11
\BOOKMARK [2][-]{subsection.2.5}{Gota}{section.2}% 12
\BOOKMARK [2][-]{subsection.2.6}{Cribatge}{section.2}% 13
\BOOKMARK [2][-]{subsection.2.7}{Malaltia de Pompe}{section.2}% 14
\BOOKMARK [2][-]{subsection.2.8}{Fibrosi qu\355stica}{section.2}% 15
\BOOKMARK [1][-]{section.3}{Malalties autos\362miques dominants}{}% 16
\BOOKMARK [2][-]{subsection.3.1}{S\355ndrome de defici\350ncia de GLUT1}{section.3}% 17
\BOOKMARK [2][-]{subsection.3.2}{Polineuropatia amilod\362ptica familiar de tipus I}{section.3}% 18
\BOOKMARK [2][-]{subsection.3.3}{Acondropl\340sia}{section.3}% 19
\BOOKMARK [2][-]{subsection.3.4}{S\355ndrome de resist\350ncia generalitzada a les hormones tiro\357dals}{section.3}% 20
\BOOKMARK [2][-]{subsection.3.5}{Osteog\350nesi imperfecta}{section.3}% 21
\BOOKMARK [1][-]{section.4}{Seminari. Lipodistr\362fies cong\350nites}{}% 22
\BOOKMARK [2][-]{subsection.4.1}{Lipodistr\362fies cong\350nites}{section.4}% 23
\BOOKMARK [2][-]{subsection.4.2}{Bases moleculars de les lipodistr\362fies cong\350nites generalitzades}{section.4}% 24
\BOOKMARK [1][-]{section.5}{Malalties del genoma mitocondrial}{}% 25
\BOOKMARK [2][-]{subsection.5.1}{Biologia del DNA mitocondrial}{section.5}% 26
\BOOKMARK [2][-]{subsection.5.2}{Mutacions al genoma mitocondrial}{section.5}% 27
\BOOKMARK [2][-]{subsection.5.3}{Her\350ncia del genoma mitocondrial}{section.5}% 28
\BOOKMARK [2][-]{subsection.5.4}{Malalties mitocondrials}{section.5}% 29
\BOOKMARK [2][-]{subsection.5.5}{Tractament de les malalties mitocondrials}{section.5}% 30
\BOOKMARK [1][-]{section.6}{Gen\350tica de la obesitat monog\350nica}{}% 31
\BOOKMARK [2][-]{subsection.6.1}{Obesitat}{section.6}% 32
\BOOKMARK [2][-]{subsection.6.2}{Obesitat monog\350nica}{section.6}% 33
\BOOKMARK [2][-]{subsection.6.3}{Obesitat multifactorial}{section.6}% 34
\BOOKMARK [1][-]{section.7}{Malalties recessives lligades al cromosoma X}{}% 35
\BOOKMARK [2][-]{subsection.7.1}{Malalties lligades al sexe}{section.7}% 36
\BOOKMARK [2][-]{subsection.7.2}{Distr\362fia muscular de Duchenne}{section.7}% 37
\BOOKMARK [2][-]{subsection.7.3}{Patr\363 d'her\350ncia de la distr\362fia muscular de Duchenne}{section.7}% 38
\BOOKMARK [2][-]{subsection.7.4}{El gen DMD}{section.7}% 39
\BOOKMARK [2][-]{subsection.7.5}{La prote\357na distrofina}{section.7}% 40
\BOOKMARK [2][-]{subsection.7.6}{Mutacions a DMD}{section.7}% 41
\BOOKMARK [2][-]{subsection.7.7}{Diagn\362stic gen\350tic}{section.7}% 42
\BOOKMARK [2][-]{subsection.7.8}{An\340lisi de lligament}{section.7}% 43
\BOOKMARK [1][-]{section.8}{Malalties dominants lligades al cromosoma X}{}% 44
\BOOKMARK [2][-]{subsection.8.1}{S\355ndrome de l'X fr\340gil}{section.8}% 45
\BOOKMARK [2][-]{subsection.8.2}{Gen FMR1}{section.8}% 46
\BOOKMARK [2][-]{subsection.8.3}{Mecanismes d'expansi\363/inestabilitat}{section.8}% 47
\BOOKMARK [2][-]{subsection.8.4}{La prote\357na FMRP}{section.8}% 48
\BOOKMARK [1][-]{section.9}{Heterogene\357tat g\350nica. Retinitis pigmentosa}{}% 49
\BOOKMARK [2][-]{subsection.9.1}{Retinitis pigmentosa}{section.9}% 50
\BOOKMARK [2][-]{subsection.9.2}{Cerca de gens implicats en la retinitis pigmentosa}{section.9}% 51
\BOOKMARK [1][-]{section.10}{Malalties cromos\362miques}{}% 52
\BOOKMARK [2][-]{subsection.10.1}{Els cromosomes}{section.10}% 53
\BOOKMARK [2][-]{subsection.10.2}{Aberracions cromos\362miques}{section.10}% 54
\BOOKMARK [2][-]{subsection.10.3}{Aberracions estructurals}{section.10}% 55
\BOOKMARK [2][-]{subsection.10.4}{S\355ndrome de Down}{section.10}% 56
\BOOKMARK [2][-]{subsection.10.5}{S\355ndrome d'Edwards}{section.10}% 57
\BOOKMARK [2][-]{subsection.10.6}{S\355ndrome de Pateau}{section.10}% 58
\BOOKMARK [2][-]{subsection.10.7}{S\355ndromde de Klinefelter}{section.10}% 59
\BOOKMARK [2][-]{subsection.10.8}{S\355ndrome de Turner}{section.10}% 60
\BOOKMARK [2][-]{subsection.10.9}{Non-sense mediated RNA decay}{section.10}% 61
\BOOKMARK [1][-]{section.11}{Imprinting i malalties relacionades}{}% 62
\BOOKMARK [2][-]{subsection.11.1}{Imprinting}{section.11}% 63
\BOOKMARK [2][-]{subsection.11.2}{Si?ndrome de Beckwith-Wiedemann}{section.11}% 64
\BOOKMARK [2][-]{subsection.11.3}{S\355ndrome de Prader-Willi i Angelman}{section.11}% 65
\BOOKMARK [1][-]{section.12}{Cerca d'un gen per exoma. Opitz C i Bohring-Opitz}{}% 66
\BOOKMARK [2][-]{subsection.12.1}{El s\355ndrome d'Opitz-C i Bohring-Opitz}{section.12}% 67
\BOOKMARK [2][-]{subsection.12.2}{Metodologia}{section.12}% 68
\BOOKMARK [2][-]{subsection.12.3}{Resultats}{section.12}% 69
\BOOKMARK [1][-]{section.13}{Defectes del tancament del tub neural}{}% 70
\BOOKMARK [2][-]{subsection.13.1}{El tub neural}{section.13}% 71
\BOOKMARK [2][-]{subsection.13.2}{Defectes del tub neural}{section.13}% 72
\BOOKMARK [2][-]{subsection.13.3}{Car\340cters multifactorials}{section.13}% 73
\BOOKMARK [2][-]{subsection.13.4}{NTD gen\350tic}{section.13}% 74
\BOOKMARK [2][-]{subsection.13.5}{Factors ambientals de risc per NTD}{section.13}% 75
\BOOKMARK [2][-]{subsection.13.6}{Factors gen\350tics pels NTD relacionats amb el folat}{section.13}% 76
\BOOKMARK [1][-]{section.14}{Osteoporosi}{}% 77
\BOOKMARK [2][-]{subsection.14.1}{Factors per la susceptibilitat a la osteoporosi}{section.14}% 78
\BOOKMARK [2][-]{subsection.14.2}{Implicaci\363 de polimorfismes del promotor del gen COLIA1 en la osteoporosi}{section.14}% 79
\BOOKMARK [2][-]{subsection.14.3}{An\340lisis de tot el genoma}{section.14}% 80
\BOOKMARK [0][-]{section*.1}{Refer\350ncies}{}% 81
